Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Direct reprogramming of urine-derived cells with inducible MyoD for modeling human muscle disease

Open access
Kim, Ellis Y., Page, Patrick, Dellefave-Castillo, Lisa M., McNally, Elizabeth M., Wyatt, Eugene J. · 2016 · Skeletal Muscle

Abstract

BACKGROUND: Cellular models of muscle disease are taking on increasing importance with the large number of genes and mutations implicated in causing myopathies and the concomitant need to test personalized therapies. Developing cell models relies on having an easily obtained source of cells, and if the cells are not derived from muscle itself, a robust reprogramming process is needed. Fibroblasts are a human cell source that works well for the generation of induced pluripotent stem cells, which can then be differentiated into cardiomyocyte lineages, and with less efficiency, skeletal muscle-like lineages. Alternatively, direct reprogramming with the transcription factor MyoD has been used to generate myotubes from cultured human fibroblasts. Although useful, fibroblasts require a skin biopsy to obtain and this can limit their access, especially from pediatric populations. RESULTS: We now demonstrate that direct reprogramming of urine-derived cells is a highly efficient and reproducible process that can be used to establish human myogenic cells. We show that this method can be applied to urine cells derived from normal individuals as well as those with muscle diseases. Furthermore, we show that urine-derived cells can be edited using CRISPR/Cas9 technology. CONCLUSIONS: With progress in understanding the molecular etiology of human muscle diseases, having a readily available, noninvasive source of cells from which to generate muscle-like cells is highly useful.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13395-016-0103-9

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Transduction of urine-derived cells (UDCs) with an iMyoD lentiviral construct for myogenic reprogramming. a General overview for generating in vitro model of human skeletal muscle using UDCs and iMyoD construct. The cells were first isolated from urine samples and then transduced with lentivirus encoding an inducible MyoD. The construct includes a 4-hydroxytamoxifen (tamoxifen, TAM) response element from the estrogen receptor (ERt) downstream of the basic helix loop helix (bHLH) DNA binding domain of MyoD. After induction with tamoxifen, cells were placed in differentiation media. b Bright-field images of isolated urine cell cultures at passage 3. Scale bar = 25 μm. c Images of immunolabeled MyoD (red) in UDCs after transduction with the iMyoD lentivirus, and iMyoD-transduced urine cells treated with tamoxifen (5 μM, 48 h). Nuclei were marked with Hoechst 33342 (blue). Scale bar = 100 μm. Inset images show increased MyoD localization to the nuclei after tamoxifen. Inset of tamoxifen-treated line 2 cells shows one nuclei with MyoD localization (left) and one without (right). Inset scale bar = 25 μm. d Lentiviral iMyoD transduction efficiency across four control urine cell lines, shown as the percent of MyoD-positive cells relative the total number of cells
Fig. 1 Transduction of urine-derived cells (UDCs) with an iMyoD lentiviral construct for myogenic reprogramming. a General overview for generating in vitro model of human skeletal muscle using UDCs and iMyoD construct. The cells were first isolated from urine samples and then transduced with lentivirus encoding an inducible MyoD. The construct includes a 4-hydroxytamoxifen (tamoxifen, TAM) response element from the estrogen receptor (ERt) downstream of the basic helix loop helix (bHLH) DNA binding domain of MyoD. After induction with tamoxifen, cells were placed in differentiation media. b Bright-field images of isolated urine cell cultures at passage 3. Scale bar = 25 μm. c Images of immunolabeled MyoD (red) in UDCs after transduction with the iMyoD lentivirus, and iMyoD-transduced urine cells treated with tamoxifen (5 μM, 48 h). Nuclei were marked with Hoechst 33342 (blue). Scale bar = 100 μm. Inset images show increased MyoD localization to the nuclei after tamoxifen. Inset of tamoxifen-treated line 2 cells shows one nuclei with MyoD localization (left) and one without (right). Inset scale bar = 25 μm. d Lentiviral iMyoD transduction efficiency across four control urine cell lines, shown as the percent of MyoD-positive cells relative the total number of cellsCC BY · PubMed Central
Fig. 2 Tamoxifen-induced myogenic reprogramming of iMyoD-transduced UDCs. a RT-PCR time course evaluation of DES (desmin) mRNA expression in two UDC lines (2 and 11). iMyoD-transduced cells were treated with or without tamoxifen (2.5 μM, 24 h) and then cultured in differentiation media as indicated (7, 14, and 28 days). GAPDH mRNA expression is shown as a control. b Real-time semi-quantitative PCR results for DES mRNA expression in urine cell lines 2 and 11. c Immunofluorescence microscopy of MyoD (red) and desmin (green) protein expression in iMyoD-transduced control lines 2 and 11, without tamoxifen treatment. In the uninduced state, MyoD demonstrated a cytoplasmic distribution, and no appreciable desmin expression was observed. Nuclei (blue); Scale bar = 100 μm. d After induction, MyoD (red) became more nuclear concomitant with cytoplasmic desmin (green) protein expression. Myotube elongation progressed over time in culture. Scale bar = 100 μm
Fig. 2 Tamoxifen-induced myogenic reprogramming of iMyoD-transduced UDCs. a RT-PCR time course evaluation of DES (desmin) mRNA expression in two UDC lines (2 and 11). iMyoD-transduced cells were treated with or without tamoxifen (2.5 μM, 24 h) and then cultured in differentiation media as indicated (7, 14, and 28 days). GAPDH mRNA expression is shown as a control. b Real-time semi-quantitative PCR results for DES mRNA expression in urine cell lines 2 and 11. c Immunofluorescence microscopy of MyoD (red) and desmin (green) protein expression in iMyoD-transduced control lines 2 and 11, without tamoxifen treatment. In the uninduced state, MyoD demonstrated a cytoplasmic distribution, and no appreciable desmin expression was observed. Nuclei (blue); Scale bar = 100 μm. d After induction, MyoD (red) became more nuclear concomitant with cytoplasmic desmin (green) protein expression. Myotube elongation progressed over time in culture. Scale bar = 100 μmCC BY · PubMed Central
Fig. 3 Myogenic differentiation and maturation of induced iMyoD UDCs. a Timeline for differentiation of iMyoD-transduced cells. b RT-PCR for myogenic maturation markers in iMyoD-transduced line 2, with or without tamoxifen (2.5 μM, 24 h), and culture in differentiation media as indicated (7, 14, and 28 days). Myogenin (MYOG) and embryonic myosin heavy chain (MYH3) were the earliest markers detected. c Real-time semi-quantitative PCR results demonstrated that dystrophin (DMD) and adult myosin heavy chain (MYH2) were detected with further differentiation. d Images of myogenic markers in iMyoD-transduced line 2. Increased muscle marker expression over time was accompanied by myotube elongation. Nuclei (blue); Scale bar = 100 μm
Fig. 3 Myogenic differentiation and maturation of induced iMyoD UDCs. a Timeline for differentiation of iMyoD-transduced cells. b RT-PCR for myogenic maturation markers in iMyoD-transduced line 2, with or without tamoxifen (2.5 μM, 24 h), and culture in differentiation media as indicated (7, 14, and 28 days). Myogenin (MYOG) and embryonic myosin heavy chain (MYH3) were the earliest markers detected. c Real-time semi-quantitative PCR results demonstrated that dystrophin (DMD) and adult myosin heavy chain (MYH2) were detected with further differentiation. d Images of myogenic markers in iMyoD-transduced line 2. Increased muscle marker expression over time was accompanied by myotube elongation. Nuclei (blue); Scale bar = 100 μmCC BY · PubMed Central
Fig. 4 Maturation of myotubes at 28-day and 35-day time points. a Bright-field images of myotube formation at the 28-day time point in iMyoD lines 2 and 11 after induction and differentiation (left panels). Middle panels show images of dystrophin (green) and α-actinin (red) protein expression, taken in the same field as the bright-field panels. The right panels show the merged images revealing dystrophin and α-actinin expressions throughout the lengths of the myotubes. Scale bar = 100 μm. b Images of iMyoD-induced UDCs after 35 days of differentiation showing expression of fast MHC, α-actinin, and titin. The magnified region of interest (ROI) is outlined in the first panels (white rectangles). White arrows highlight the membrane localization of dystrophin (green). White arrowheads highlight the formation of sarcomeres (red). Scale bar = 25 μm
Fig. 4 Maturation of myotubes at 28-day and 35-day time points. a Bright-field images of myotube formation at the 28-day time point in iMyoD lines 2 and 11 after induction and differentiation (left panels). Middle panels show images of dystrophin (green) and α-actinin (red) protein expression, taken in the same field as the bright-field panels. The right panels show the merged images revealing dystrophin and α-actinin expressions throughout the lengths of the myotubes. Scale bar = 100 μm. b Images of iMyoD-induced UDCs after 35 days of differentiation showing expression of fast MHC, α-actinin, and titin. The magnified region of interest (ROI) is outlined in the first panels (white rectangles). White arrows highlight the membrane localization of dystrophin (green). White arrowheads highlight the formation of sarcomeres (red). Scale bar = 25 μmCC BY · PubMed Central
Fig. 5 Myogenic reprogramming of LGMD2C UDCs. a Schematic showing exon organization of the γ-sarcoglycan (SGCG) mRNA transcript and two LGMD2C patients with frameshifting deletions affecting the SGCG locus that lead to premature stop codons (red triangles). One has a deletion of exons 5 and 6 (ex5/6del), and the other has a deletion of exon 7 (ex7del). RT-PCR demonstrated SGCG transcripts from UDCs after treatment with tamoxifen (2.5 μM, 24 h) and culture in differentiation media for 28d. Orange arrowheads indicate the mutant transcripts lacking the expected exons. b Real-time semi-quantitative PCR results demonstrate myogenic reprogramming of ex5/6del (top) and ex7del (bottom) after treatment with tamoxifen (2.5 μM, 24 h) and culture in differentiation media as indicated (7, 14, and 28 days). c Images of myogenic markers in iMyoD control and LGMD2C ex5/6del and ex7del patient-derived lines. LGMD2C patient-derived cells formed myotubes comparable to those of control cells. Nuclei (blue); Scale bar = 50 μm. d Desmin, α-actinin, dystrophin, and fast MHC were expressed in LGMD2C cells. γ-sarcoglycan (green) was not detected. White boxes outline double-labeled regions of interest (ROI) enlarged in far right panels. Images show γ-sarcoglycan expression and localization to the membrane in line 11, as opposed to no detectable expression of γ-sarcoglycan in LGMD2C patient myotubes. Scale bar = 100 μm in left and middle panels; 50 μm in right panels
Fig. 5 Myogenic reprogramming of LGMD2C UDCs. a Schematic showing exon organization of the γ-sarcoglycan (SGCG) mRNA transcript and two LGMD2C patients with frameshifting deletions affecting the SGCG locus that lead to premature stop codons (red triangles). One has a deletion of exons 5 and 6 (ex5/6del), and the other has a deletion of exon 7 (ex7del). RT-PCR demonstrated SGCG transcripts from UDCs after treatment with tamoxifen (2.5 μM, 24 h) and culture in differentiation media for 28d. Orange arrowheads indicate the mutant transcripts lacking the expected exons. b Real-time semi-quantitative PCR results demonstrate myogenic reprogramming of ex5/6del (top) and ex7del (bottom) after treatment with tamoxifen (2.5 μM, 24 h) and culture in differentiation media as indicated (7, 14, and 28 days). c Images of myogenic markers in iMyoD control and LGMD2C ex5/6del and ex7del patient-derived lines. LGMD2C patient-derived cells formed myotubes comparable to those of control cells. Nuclei (blue); Scale bar = 50 μm. d Desmin, α-actinin, dystrophin, and fast MHC were expressed in LGMD2C cells. γ-sarcoglycan (green) was not detected. White boxes outline double-labeled regions of interest (ROI) enlarged in far right panels. Images show γ-sarcoglycan expression and localization to the membrane in line 11, as opposed to no detectable expression of γ-sarcoglycan in LGMD2C patient myotubes. Scale bar = 100 μm in left and middle panels; 50 μm in right panelsCC BY · PubMed Central
Fig. 6 Myogenic reprogramming of DMD patient-derived urine cells. a Schematic showing organization of dystrophin exons 42 to 51 (top) and DMD patient with a frameshift deletion of exons 46 and 47 (bottom). RT-PCR demonstrated DMD transcript expression from iMyoD-transduced line 11 control and DMD ex46/47del mutant cell lines, after tamoxifen induction (2.5 μM, 24 h) and differentiation as indicated. Blue arrows indicate the location of the outer primers that produce the PCR products in the gel below. Red arrows indicate nested primers used to generate transcripts used for sequencing. b Sequencing results from RT-PCR products from iMyoD-reprogrammed urine-derived cells. The sequenced transcripts were generated from a set of nested primers (red) shown in a. Line 11 showed the expected exon45-exon46 and exon47-exon48 junctions. The ex46/47del DMD individual shows the out-of-frame mutant exon45-exon48 junction. c Immunofluorescence images of iMyoD line 17 and DMD ex46/47del cells labeled with dystrophin using the NCL-DYSB antibody to dystrophin. The antibody to dystrophin showed membrane localization of dystrophin in control cells (top). No dystrophin was detected in DMD patient-derived myotubes. Scale bar = 50 μm
Fig. 6 Myogenic reprogramming of DMD patient-derived urine cells. a Schematic showing organization of dystrophin exons 42 to 51 (top) and DMD patient with a frameshift deletion of exons 46 and 47 (bottom). RT-PCR demonstrated DMD transcript expression from iMyoD-transduced line 11 control and DMD ex46/47del mutant cell lines, after tamoxifen induction (2.5 μM, 24 h) and differentiation as indicated. Blue arrows indicate the location of the outer primers that produce the PCR products in the gel below. Red arrows indicate nested primers used to generate transcripts used for sequencing. b Sequencing results from RT-PCR products from iMyoD-reprogrammed urine-derived cells. The sequenced transcripts were generated from a set of nested primers (red) shown in a. Line 11 showed the expected exon45-exon46 and exon47-exon48 junctions. The ex46/47del DMD individual shows the out-of-frame mutant exon45-exon48 junction. c Immunofluorescence images of iMyoD line 17 and DMD ex46/47del cells labeled with dystrophin using the NCL-DYSB antibody to dystrophin. The antibody to dystrophin showed membrane localization of dystrophin in control cells (top). No dystrophin was detected in DMD patient-derived myotubes. Scale bar = 50 μmCC BY · PubMed Central
Fig. 7 CRISPR/Cas9-mediated gene editing in UDCs. a Targeting strategy to introduce the 521ΔT point mutation into control SGCG exon 6 through gRNA guided, Cas9 nuclease generated double strand DNA break (DSB) with ssODN-mediated HDR repair. A portion of the SGCG exon 6 coding region is shown; a single T was removed from the 5T sequence region (cyan box). The downstream gRNA target sequence is highlighted in blue, the PAM sequence in pink, and the Cas9 DSB indicated by a yellow triangle. Below it is a portion of the 142 bp ssODN HDR repair template encoding the single T deletion along with a downstream G > A synonymous mutation (green) that destroys the PAM sequence and introduces an Alu1 restriction site. b Summary of efficiency of CRISPR/Cas9 protocol. c Alu1 restriction digest of a PCR-amplified genomic region including SGCG exon 6 and the flanking intronic sequences. d Left, partial summary of the Sanger sequencing results from individual line 2 edited clones. Right, the DNA trace from an unedited control and a clone with a homozygous deletion of a single T from the 5T of SGCG exon 6, recreating the most common LGMD2C mutation
Fig. 7 CRISPR/Cas9-mediated gene editing in UDCs. a Targeting strategy to introduce the 521ΔT point mutation into control SGCG exon 6 through gRNA guided, Cas9 nuclease generated double strand DNA break (DSB) with ssODN-mediated HDR repair. A portion of the SGCG exon 6 coding region is shown; a single T was removed from the 5T sequence region (cyan box). The downstream gRNA target sequence is highlighted in blue, the PAM sequence in pink, and the Cas9 DSB indicated by a yellow triangle. Below it is a portion of the 142 bp ssODN HDR repair template encoding the single T deletion along with a downstream G > A synonymous mutation (green) that destroys the PAM sequence and introduces an Alu1 restriction site. b Summary of efficiency of CRISPR/Cas9 protocol. c Alu1 restriction digest of a PCR-amplified genomic region including SGCG exon 6 and the flanking intronic sequences. d Left, partial summary of the Sanger sequencing results from individual line 2 edited clones. Right, the DNA trace from an unedited control and a clone with a homozygous deletion of a single T from the 5T of SGCG exon 6, recreating the most common LGMD2C mutationCC BY · PubMed Central
Fig. 8 Overview of options for modeling skeletal muscle disease in cell culture. Primary cell sources for establishing cell cultures include the muscle, skin, urine, and blood. Myoblasts cultured from muscle biopsies require approximately 3 to 4 weeks for expansion and an additional 2 weeks of culture for myotube differentiation [46–48]. Primary dermal fibroblasts isolated from skin biopsies require 3 to 4 weeks for expansion. Fibroblasts can then be transduced with inducible MyoD (iMyoD) lentivirus, expanded, and differentiated to yield myotubes by approximately 8 weeks [12, 14]. Urine cells require 3 to 4 weeks for expansion and a similar time frame for iMyoD-induced myotube formation as dermal fibroblasts. Lymphocytes isolated from blood are typically transformed using Epstein-Barr virus (EBV) to generate lymphoblastoid cell lines (LCLs), which requires 3 to 4 weeks. Fibroblasts, urine-derived cells, and LCLs can all be reprogrammed to induced pluripotent stem cells (iPSCs). Once generated and expanded, iPSCs will be subjected to quality control measures such as immunofluorescence for pluripotency markers, karyotyping, and embryoid body formation or teratoma formation for three germ layers. As each laboratory has its own quality control measures, this process will add variable amount of time for iPSC culture (indicated by hatch marks). iPSCs can be readily differentiated into cardiomyocytes [4, 49, 50]. Improved efficiency for myotube differentiation from iPSCs has been reported, but additional advances are expected to enhance the efficiency of this process [6, 7]
Fig. 8 Overview of options for modeling skeletal muscle disease in cell culture. Primary cell sources for establishing cell cultures include the muscle, skin, urine, and blood. Myoblasts cultured from muscle biopsies require approximately 3 to 4 weeks for expansion and an additional 2 weeks of culture for myotube differentiation [46–48]. Primary dermal fibroblasts isolated from skin biopsies require 3 to 4 weeks for expansion. Fibroblasts can then be transduced with inducible MyoD (iMyoD) lentivirus, expanded, and differentiated to yield myotubes by approximately 8 weeks [12, 14]. Urine cells require 3 to 4 weeks for expansion and a similar time frame for iMyoD-induced myotube formation as dermal fibroblasts. Lymphocytes isolated from blood are typically transformed using Epstein-Barr virus (EBV) to generate lymphoblastoid cell lines (LCLs), which requires 3 to 4 weeks. Fibroblasts, urine-derived cells, and LCLs can all be reprogrammed to induced pluripotent stem cells (iPSCs). Once generated and expanded, iPSCs will be subjected to quality control measures such as immunofluorescence for pluripotency markers, karyotyping, and embryoid body formation or teratoma formation for three germ layers. As each laboratory has its own quality control measures, this process will add variable amount of time for iPSC culture (indicated by hatch marks). iPSCs can be readily differentiated into cardiomyocytes [4, 49, 50]. Improved efficiency for myotube differentiation from iPSCs has been reported, but additional advances are expected to enhance the efficiency of this process [6, 7]CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

See all 46

Metadata

Authors
Kim, E. Y., Page, P., Dellefave-Castillo, L. M., McNally, E. M., & Wyatt, E. J.
Affiliations
  • University of Chicago (US)
  • Northwestern University (US)
Corresponding author
  • McNally, Elizabeth M.
  • Wyatt, Eugene J.
Venue
Skeletal Muscle
Published
2016-09-15
Volume
6
Issue
1
Pages
32-32
ISSN
2044-5040 (ISSN-L)
OpenAlex
W2519862918
Cited by
43
References
52
Citations by year
2026: 1 · 2024: 6 · 2023: 1 · 2022: 6 · 2021: 3 · 2020: 7 · 2019: 7 · 2018: 7 · 2017: 5
FWCI
3.29
Type
journal article
Language
en
Open access
Licence
Locations
  • Skeletal Muscle (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (HL61322, T32 HD009007)
  • Kurt+Peter Foundation
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
Keywords
direct reprogramming, urine-derived cells, MyoD, myogenesis, myopathy, CRISPR/Cas9 genome editing, myotubes
MeSH terms
Gene Editing, Cell Differentiation, Cells, Cultured, Clone Cells, Humans, Muscular Diseases, Muscular Dystrophies, Urine, MyoD Protein, Cell Culture Techniques, Muscle Development, Clustered Regularly Interspaced Short Palindromic Repeats, Cellular Reprogramming

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Direct reprogramming of urine-derived cells with inducible MyoD for modeling human muscle disease. https://app.cochat.ai/papers/10.1186/s13395-016-0103-9
The paper
Kim, E. Y., Page, P., Dellefave-Castillo, L. M., McNally, E. M., & Wyatt, E. J. (2016). Direct reprogramming of urine-derived cells with inducible MyoD for modeling human muscle disease. Skeletal Muscle. https://doi.org/10.1186/s13395-016-0103-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.